SCHEMBL3007130

SCHEMBL3007130

COc1ccc(OC)c(-c2csc(N3CCC(S(=O)(=O)c4c(C(C)C)cc(C(C)C)cc4C(C)C)CC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REV1 Q9UBZ9 1/20 0.48
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 7/20 0.40
AR P10275 1/20 0.40
NPC1 O15118 5/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 3/20 0.37
TDP1 Q9NUW8 1/20 0.37
HSD17B10 Q99714 3/20 0.37
ALDH1A1 P00352 2/20 0.37
USP2 O75604 1/20 0.37
RECQL P46063 1/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
OGA O60502 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014581 0.93 AR (0.46) REV1RAB9ASMN1; SMN2MAPTAR
SCHEMBL3004587 0.90 AR (0.45) REV1RAB9ASMN1; SMN2MAPTAR
SCHEMBL3008234 0.88 SMN1; SMN2 (0.55) RAB9ASMN1; SMN2MAPTARNPC1
SCHEMBL2998091 0.86 REV1 (0.51) REV1RAB9ASMN1; SMN2MAPTAR
SCHEMBL3018661 0.86 SMN1; SMN2 (0.54) RAB9ASMN1; SMN2MAPTNPC1MEN1
SCHEMBL3014196 0.85 MAPT (0.53) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3016358 0.85 REV1 (0.51) REV1RAB9ASMN1; SMN2MAPTAR
SCHEMBL3010531 0.85 SMN1; SMN2 (0.44) RAB9ASMN1; SMN2MAPTNPC1MEN1
SCHEMBL3017918 0.84 RAB9A (0.36) REV1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL3013524 0.84 REV1 (0.51) REV1RAB9ASMN1; SMN2MAPTAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA REV1 4692/4885RAB9A 2943/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.